The Institute is organized around a new collaborative model for biomedical research. It involves faculty from across Rockefeller, the California Institute of Technology, the Chan Zuckerberg Biohub, Karolinska Institute, the University of North Carolina, the COVID Human Genetic Effort, as well as investigators in Brazil, Mexico, the Czech Republic, Israel, Senegal, South Africa, Pakistan, China, and Taiwan.
We have entered into a framework agreement with the Institute for Research in Biomedicine in Bellinzona, Switzerland to engage in infectious disease research on a global basis. The first project that will benefit from this collaboration is the development and clinical testing of a patient-derived monoclonal antibody against Tick Borne Encephalitis Virus.
